Task Force 5: Clinical Considerations for Myocarditis and Selected Cardiovascular Conditions, Including Valvular Heart Disease

Athletes with myocarditis, pericarditis, valvular heart disease, and other acquired cardiovascular conditions require careful evaluation when considering competitive sports participation. This document outlines key clinical considerations, risk factors, and expert consensus, serving as the rationale for Section V of the recent AHA/ACC Scientific Statement: Clinical Considerations for Competitive Sports Participation for Athletes with Cardiovascular Abnormalities. Disease-specific risk stratification and shared decision-making are essential in determining return-to-play eligibility. This Task Force document addresses myocarditis, pericarditis, the cardiovascular impact of respiratory viral infections, incidental myocardial fibrosis, Kawasaki disease, infiltrative cardiomyopathies, and valvular heart disease.

Authors

Institutions

Publication Details

Journal
Medicine & Science in Sports & Exercise
Published
2026-11-13
DOI
https://doi.org/10.1249/mss.0000000000004093
Primary Topic
Cardiovascular Effects of Exercise
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Task Force 5: Clinical Considerations for Myocarditis and Selected Cardiovascular Conditions, Including Valvular Heart Disease

James Sawalla Guseh, Jonathan H. Kim, Aaron Leigh Baggish, Matthias Wilhelm et al.
6 links
Medicine & Science in Sports & Exercise
Cardiovascular Effects of Exercise
article

Task Force 5: Clinical Considerations for Myocarditis and Selected Cardiovascular Conditions, Including Valvular Heart Disease

James Sawalla Guseh, Jonathan H. Kim, Aaron Leigh Baggish, Matthias Wilhelm, SILVIA CASTELLETTI, MATTHEW W. MARTINEZ, BENJAMIN D. LEVINE, LARRY A. ALLEN
article en

Abstract

Athletes with myocarditis, pericarditis, valvular heart disease, and other acquired cardiovascular conditions require careful evaluation when considering competitive sports participation. This document outlines key clinical considerations, risk factors, and expert consensus, serving as the rationale for Section V of the recent AHA/ACC Scientific Statement: Clinical Considerations for Competitive Sports Participation for Athletes with Cardiovascular Abnormalities. Disease-specific risk stratification and shared decision-making are essential in determining return-to-play eligibility. This Task Force document addresses myocarditis, pericarditis, the cardiovascular impact of respiratory viral infections, incidental myocardial fibrosis, Kawasaki disease, infiltrative cardiomyopathies, and valvular heart disease.

Medicine & Science in Sports & ExerciseVol. 58(12)
University of Bern (CH), Emory University (US), Texas Health Dallas (US), University Hospital of Bern (CH), Centre Hospitalier Universitaire Vaudois (CH), Morristown Medical Center (US), Massachusetts General Hospital (US), IRCCS Istituto Auxologico Italiano (IT), Institute for Exercise and Environmental Medicine (US), University of Colorado Anschutz Medical Campus (US), Atlantic Health System (US), The University of Texas Southwestern Medical Center (US), University of Colorado Denver (US)
Good health and well-being
Cardiovascular Effects of Exercise
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon